Drugs / REGN17092
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05923424 | Nov 2023 → Mar 2025 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN17092 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05923424 ↗ |
| Modality | Monoclonal antibody | “an Anti-SARS-CoV-2 (COVID-19) Monoclonal Antibody” NCT05923424 ↗ |
| Route | Intravenous | “Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol” NCT05923424 ↗ |
| Route | Subcutaneous | “Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol” NCT05923424 ↗ |